title: Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy.
abstract: The aim of the study was to evaluate whether adequate stem cells (CD34+) could be harvested at presentation in myeloma patients such that high dose melphalan (HDM) with autologous stem cell rescue can be offered as primary therapy. The regimes either involved no prior cytoreductive chemotherapy (steroids only, n = 31) or a single course of VAD (n = 22). The median number of CD34 cells collected with steroids was 1.3 x 10(6) (0.2-5.6) compared to 4.6 x 10(6) (0.3-19.2) cells/kg with VAD (P < 0.0001). We conclude that it is possible to collect stem cells from myeloma patients at presentation with minimal prior therapy. Using this strategy, of a single prior course of chemotherapy followed by immediate harvest, it is feasible to offer early high-dose therapy in clinical situations where this is important.
authors: Haemato-Oncology Unit, Royal Marsden Hospital (RMH) and Institute of Cancer Research, Sutton, Surrey. UK.
authors: Bhawna
authors: B
authors: Sirohi
authors: Ray
authors: R
authors: Powles
authors: Jamie
authors: J
authors: Cavanagh
authors: Heather
authors: H
authors: Oakervee
authors: P
authors: P
authors: Dyer
authors: T
authors: T
authors: Rintala
authors: Samar
authors: S
authors: Kulkarni
authors: Claudius
authors: C
authors: Rudin
authors: Clive
authors: C
authors: Horton
authors: Jennifer
authors: J
authors: Treleaven
authors: Gareth
authors: G
authors: Morgan
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001772:Blood Cell Count; D003520:Cyclophosphamide / Q000494:pharmacology; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D000078224:Lenograstim; D007937:Leukapheresis; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008775:Methylprednisolone / Q000494:pharmacology; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D036102:Peripheral Blood Stem Cell Transplantation; D011994:Recombinant Proteins / Q000494:pharmacology; D012074:Remission Induction; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D000078224:Lenograstim; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D000069585:Filgrastim; D008558:Melphalan; D008775:Methylprednisolone